Epstein-Barr virus-positive diffuse large B-cell lymphoma Advocacy Hub | UniteRare

12.1 Mechanism of Action Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecu...

FDA label ↗

Breyanzi

(lisocabtagene maraleucel)Orphan drugstandard

Juno Therapeutics, Inc.

12.1 Mechanism of Action BREYANZI is a CD19-directed genetically modified autologous cell immunotherapy administered as a defined composition to reduc...

FDA label ↗

Epkinly

(epcoritamab-bysp)Orphan drugaccelerated

Genmab US, Inc.

Bispecific CD20-directed CD3 T Cell Engager [EPC]

12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells ...

FDA label ↗

Zynlonta

(loncastuximab tesirine-lpyl)Orphan drugaccelerated

ADC Therapeutics SA

12.1 Mechanism of Action Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component ...

FDA label ↗

Kymriah

(tisagenlecleucel)Orphan drugstandard

Novartis Pharmaceuticals Corporation

CD19-directed Chimeric Antigen Receptor [EPC]

12.1 Mechanism of Action KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy which involves reprogramming a patient’s own ...

FDA label ↗

MONJUVI

(tafasitamab-cxix)Orphan drugaccelerated

Incyte Corporation

12.1 Mechanism of Action Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and matur...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

18 active trials

3Phase 3

6Phase 2

3Phase 1

1N/A

3Unknown

1EARLY_PHASE1

1PHASE2, PHASE3

18Total recruiting

Search clinical trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →

Recent News & Research

6 articles

BREAKINGFDA

FDA Approves POLIVY

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) received FDA approval.

Read ↗

Annals of hematologyApr 17, 2026

Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China.

Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) is a rare and clinically aggressive subtype of DLBCL, distinguished by its notably unfavorable prognosis. The clinical characteris...

Read ↗

Cell death & diseaseMar 26, 2026

Long noncoding RNA ADEI/miR-93-3p/STAT3 axis promotes Epstein-Barr virus-positive diffuse large B-cell lymphoma progression and immune evasion through regulating the PD-1/PD-L1 checkpoint.

Epstein-Barr virus (EBV) is an important pathogenic factor of lymphoma; EBV+diffuse large B-cell lymphoma (DLBCL) has a worse prognosis with standard chemotherapy than EBV-DLBCL. Long noncoding (Lnc)-...

Read ↗

Frontiers in medicineMar 2, 2026

Case Report: Rare pulmonary infection and cytomegalovirus retinitis revealed a case of lymphoma.

Recurrent cytomegalovirus retinitis (CMVR) and rare opportunistic pulmonary infections may be the initial manifestations of underlying immunodeficiency caused by occult hematologic malignancy. Epstein...

Read ↗

Annals of African medicineFeb 23, 2026

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma Presenting as Pyrexia of Unknown Origin Complicated by Paraneoplastic Neurological Syndrome.

Chikungunya virus (CHIKV) infection is an arboviral disease transmitted by Aedes mosquitoes, typically presenting with fever, rash, and polyarthralgia. Neurological complications such as meningitis ar...

Read ↗

Hematology (Amsterdam, Netherlands)Feb 11, 2026

Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study.

To analyze the clinical characteristics and prognosis of Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV + DLBCL) in a Chinese cohort. Fifty-seven EBV + DLBCL patients (diagnosed betwee...

Read ↗

Browse all Epstein-Barr virus-positive diffuse large B-cell lymphoma news →